Evidence map›Paper›PMID 34830188›Full record

ReviewInternational journal of molecular sciences2021

Genetic and Enzymatic Characteristics of CYP2A13 in Relation to Lung Damage.

Radim Vrzal

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Genomic signatures of selection in drug metabolizing genes across cattle populations.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
  3. Article
  4. PharmVar GeneFocus: CYP2A6.Clinical pharmacology and therapeutics · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Radim VrzalDepartment of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic.ORCID 0000-0001-9251-2414
Palacký University Olomouc · CZ

Funding

Czech Health Research Council NV19-05-00220
6 · The paper itself

Abstract

Cytochrome P450 2A13 is an omitted brother of CYP2A6 that has an important role in the drug metabolism of liver. Due to extrahepatic expression, it has gained less attention than CYP2A6, despite the fact that it plays a significant role in toxicant-induced pulmonary lesions and, therefore, lung cancer. The purpose of this mini-review is to summarize the basic knowledge about this enzyme in relation to the substrates, inhibitors, genetic polymorphisms, and transcriptional regulation that are known so far (September 2021).

Indexed as

Gene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticPolymorphism, GeneticAnimalsAryl Hydrocarbon HydroxylasesHumansLungLung NeoplasmsMethoxsalenSubstrate SpecificityAryl Hydrocarbon HydroxylasesCYP2A13 protein, humanMethoxsalenaflatoxinFOXA2lung cancerNNKpolymorphismregulationskatole

Identifiers

PMID34830188
PMCPMC8625632
OpenAlexW3211850712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.